文献速递中医内科中药与中成药合理使用

紫翠饮治疗糖尿病肾病的多中心随机对照试验

Efficacy and safety of Zicuiyin decoction on diabetic kidney disease: A multicenter, randomized controlled trial.
PubMed 文献 · Phytomedicine · 2022-04-02

本研究为多中心、平行对照、开放标签随机试验,纳入88例糖尿病肾病患者,比较紫翠饮与黄葵胶囊治疗8周的效果。主要终点为eGFR变化,紫翠饮组eGFR变化为2.57±18.49 ml/min/1.73 m2,黄葵胶囊组为-7.08±24.65 ml/min/1.73 m2(p<0.05),且紫翠饮在降低SCr和症状积分方面更优,并可改善肠道菌群失调。

要点

  • 紫翠饮在改善eGFR方面优于黄葵胶囊,且差异有统计学意义。
  • 紫翠饮可显著降低血肌酐和症状积分。
  • 紫翠饮可调节肠道菌群,增加Prevotellaceae和Lactobacillaceae。

核心结论

  • 紫翠饮在改善和保护肾功能方面疗效优于黄葵胶囊,可作为糖尿病肾病的替代治疗选择,尤其适用于eGFR下降和肠道菌群失调者。

研究设计与样本

  • 多中心、平行对照、开放标签、随机对照试验,于天津3个中心招募88例糖尿病肾病患者,随机分为黄葵胶囊组(2.5 g,每日三次)和紫翠饮组(生药量75 g,150 ml,每日两次),治疗8周。

主要发现

  • 紫翠饮组eGFR变化为2.57±18.49 ml/min/1.73 m2,黄葵胶囊组为-7.08±24.65 ml/min/1.73 m2(p<0.05),估计均值差的95%置信下限为1.93 ml/min/1.73 m2。
  • 与黄葵胶囊相比,紫翠饮可显著降低血肌酐和症状积分(p<0.05)。
  • 两组在其他结局指标上无显著差异(p>0.05)。
  • 紫翠饮可改善肠道菌群失调,增加Prevotellaceae和Lactobacillaceae,减少Enterobacteriales、Clostridiaceae和Micrococcaceae。
  • 两组均未报告严重不良事件。

关键数值与推荐

  • 主要终点eGFR变化:紫翠饮组2.57±18.49 ml/min/1.73 m2,黄葵胶囊组-7.08±24.65 ml/min/1.73 m2(p<0.05)。
  • 估计均值差的95%置信下限为1.93 ml/min/1.73 m2,确立紫翠饮的优效性。

临床怎么用

  • 对于糖尿病肾病患者,尤其是eGFR下降和肠道菌群失调者,可考虑使用紫翠饮作为黄葵胶囊的替代治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUD: Zicuiyin (ZCY) decoction created by Xichun Zhang in the Qing dynasty has been used on diabetes mellitus and complications for more than two centuries in China. Huangkui capsule (HKC) is a listed Chinese patent medicine to treat diabetic kidney disease (DKD). To determine whether ZCY is non-inferior to HKC in the treatment of DKD, a multicenter, parallel-control, open-label, randomized clinical trial was conducted. METHODS: In this clinical trial, 88 DKD patients were recruited at three centers in Tianjin from January 2018 to December 2019. They were randomized to receive HKC (2.5 g, TID) or ZCY (crude drug amount 75 g, 150 ml, BID) for eight weeks based on routine treatment. The primary outcome was the change of estimated glomerular filtration rate (eGFR). The secondary outcomes included change of serum creatinine (SCr), urinary albumin excretion rate, 24 h urinary protein, urinary albumin-creatinine ratio, glycosylated hemoglobin A1c, symptom scores, and microbiota compositions profiles. RESULTS: The change of eGFR in HKC and ZCY groups were -7.08 ± 24.65 and 2.57 ± 18.49 ml/min/1.73 m2, respectively (p < 0.05). The 95% lower confidence limit for the difference between the estimated means was 1.93 ml/min/1.73 m2, establishing the superiority of ZCY. Compared to HKC, ZCY could significantly decrease SCr and symptom scores (p < 0.05). There were no significant differences in other outcomes between the two groups (p > 0.05). ZCY ameliorated gut microbiota dysbiosis, including increased Prevotellaceae and Lactobacillaceae and decreased Enterobacteriales, Clostridiaceae and Micrococcaceae. No severe adverse events were reported in any group. CONCLUSIONS: ZCY had better efficacy in improving and protecting kidney function. It would be an alternative option to treat DKD, especially those who decline eGFR and gut microbiota dysbiosis. TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR-OON-17012076. Registered July 21, 2017.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Liu J, Gao LD, Fu B, et al. Efficacy and safety of Zicuiyin decoction on diabetic kidney disease: A multicenter, randomized controlled trial. Phytomedicine. 2022. PMID: 35413644. doi:10.1016/j.phymed.2022.154079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。